Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics
Presage Sets the Stage for Commercial Expansion with Closing of $13M Financing and Execution of New Phase 0 Trial Agreements with Merck and Maverick Therapeutics
03/02/21, 12:19 PM
Location
seattle
Money raised
$13 million
Presage Biosciences, Inc., a biotechnology company pioneering a new cancer drug development approach using its Comparative In Vivo Oncology (CIVO®) intratumoral microdosing platform, today announced the closing of a $13 million financing and commencement of new research collaborations with Merck, known as MSD outside of the United States and Canada, and Maverick Therapeutics.
Company Info
Company
Civo And Phase 0 Trials
Location
seattle, washington, united states
Additional Info
Comparative In Vivo Oncology (CIVO) is Presage's patented platform that enables intratumoral microdosing and analysis of multiple cancer agents. Phase 0 trials, or Exploratory Investigational New Drug studies, allow for the evaluation of minute amounts of drugs in patients to assess pharmacodynamic effects. Presage is advancing the use of CIVO in Phase 0 trials in order to rapidly evaluate multiple drug candidates and enhance knowledge applicable for future trial design. A recently completed clinical trial demonstrated that CIVO is well tolerated and highlighted drug-specific tumor cell and microenvironment responses to both small molecule and biologic agents.